ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PBLS
VKTX (43) ACAD (49) IRON (54) AMLX (39) ⌘ Pro Terminal →

Parabilis Medicines Inc. (PBLS) — RQD Stock Rating Cockpit

$27.25 -3.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.01

Parabilis Medicines Inc. (PBLS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.45B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBLS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Parabilis Medicines Inc. (NASDAQ: PBLS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $27.25 (-3.78% 1D, market cap $3.45B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PBLS ranks #299 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBLS compare to VKTX and ACAD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBLS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VKTX (Viking Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.48B) and ACAD (ACADIA Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.55B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBLS?
▼

Per PBLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001657677), Parabilis Medicines Inc. generated $33.9M in revenue, $0 in net income, and $0 in free cash flow against $80.8M in total assets and $600.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $27.01 (-0.87%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 284.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (6)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$45 Bull$26 Base$20 Bear
📬 FREE PBLS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBLS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY PBLS SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 284.9% FCF Margin ($96.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$26.85+0.9% Next Q
Q2 (-2Q)
42
Grade D$27.08-2.1% Next Q
Q3 (-1Q)
44
Grade D$26.51+2.8% Next Q
Current
47
Grade D$27.25-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PBLS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PBLS currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.54) and Max Pain ($28.61) forces dealer call-delta covering toward $44.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE23% OF RANGE
L: $23$27.25H: $42
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on PBLS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

15/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like PBLS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBLS)

  • ✓Walkthrough of PBLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PBLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.77%📐 HORIZONTAL RANGE
2026-11-03O $28.70H $28.70L $27.25C $27.25VOL 814.0K
RES: $44.09SUP: $22.40SMA50: $32.54SMA200: $32.15
$43.88$38.13$32.38$26.63$20.88RES $44.09SUP $22.40$27.252026-06-102026-07-172026-08-212026-09-282026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBLS Butterfly Map → + Track PBLS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PBLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBLS)

Health Care Rank #299 of 1015 ⚔️ VKTX vs PBLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBLS vs. VKTX, ACAD, IRON, AMLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Parabilis Medicines Inc. (PBLS) ranks #299 by composite RQD confidence (47/100, grade D) and #194 by equity capitalization ($3.45B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while ACAD leads on capital efficiency and profitability with 7.9% ROIC and 91.7% gross margin. IRON currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with PBLS at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PBLS ACTIVE
Parabilis Medicines Inc.
D 47/100 — — — -3.78% $3.45B Benchmark Subject
VKTX
Viking Therapeutics Inc.
D- 43/100 — — -35.0% -1.65% $3.48B /vktx-vs-pbls →
ACAD
ACADIA Pharmaceuticals Inc.
D 49/100 9.1x 91.7% 7.9% -0.58% $3.55B /acad-vs-pbls →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.75% $3.59B /iron-vs-pbls →
AMLX
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.84% $3.62B /amlx-vs-pbls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001657677 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Parabilis Medicines Inc. (PBLS) reported GAAP revenue of $33.9M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PBLS closed FY2025 with $80.8M in total assets against $600.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $33.9M $0 — — $80.8M $600.0K

3. PBLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Parabilis Medicines Inc. (NASDAQ: PBLS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $27.25 (-3.78% 1D, market cap $3.45B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PBLS ranks #299 in composite RQD confidence.

How does PBLS compare to VKTX and ACAD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBLS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VKTX (Viking Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.48B) and ACAD (ACADIA Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.55B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBLS?

Per PBLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001657677), Parabilis Medicines Inc. generated $33.9M in revenue, $0 in net income, and $0 in free cash flow against $80.8M in total assets and $600.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBLS trading relative to its 50-day, 200-day, and 52-week technical levels?

PBLS last traded at $27.25 (-3.78% on volume of 702,273 shares), positioning the stock -16.26% below its 50-day simple moving average ($32.54) and -15.24% below its 200-day simple moving average ($32.15). Across its 52-week range of $22.66 to $42.49, PBLS sits at the 23.1% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($23.84 to $30.66).

Direct Sub-Reports: PBLS RQD Cockpit PBLS 12M Forecast PBLS Earnings & Move PBLS Dividends & DRIP PBLS Insiders & 13F PBLS Whale Options PBLS Profit Sankey PBLS News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

PBLS — Parabilis Medicines Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Parabilis Medicines Inc. (PBLS) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $27.25 (-3.78% 1D, market capitalization $3.45B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Parabilis Medicines Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The profile reports a market capitalization of $3.5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Parabilis Medicines Inc. (PBLS) reported $33.9M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $80.8M in total assets against $600.0K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $22.66 – $42.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PBLS carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can PBLS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $33.9M and free cash flow of $0, how will capital allocation balance growth reinvestment against $600.0K in total debt?
  • Key Question #3: How sensitive is PBLS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PBLS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Parabilis Medicines Inc. (PBLS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PBLS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PBLS Bull vs. Bear Conversation Board — What's Your Call at $27.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBLS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PBLS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $32.85 (+16.0%)
📌 Pinned Debate

A Seeking Alpha piece flagged as a GREEN catalyst reports bullishness on zolucatetide's broad oncology potential, and the balance sheet

Picked up a starter position in PBLS in my $100K Virtual Cash book at $28.32. A Seeking Alpha piece flagged as a GREEN catalyst reports bullishness on zolucatetide's broad oncology potential, and the balance sheet scores 13/20 with $27.7M cash against $0.6M debt.. Trading inside a $22.66–$42.49 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 6/20 institutional whale-flow stock at $28.32 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $22.37 (-21.0%)
Spot @ $28.32

Measured ROIC and FCF yield are both 0% with zero FY 2025 revenue and net income, and insider and whale pillars score 9/20 and 6/20.

Fading this rally in PBLS at $28.32. Measured ROIC and FCF yield are both 0% with zero FY 2025 revenue and net income, and insider and whale pillars score 9/20 and 6/20.. With a beta of 1.0 and the stock sitting at $28.32 (52-wk range $22.66–$42.49), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%